Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Acta Neuropathol. 2020 Jan;139(1):193-209. doi: 10.1007/s00401-019-02078-w. Epub 2019 Sep 28.
The "isomorphic subtype of diffuse astrocytoma" was identified histologically in 2004 as a supratentorial, highly differentiated glioma with low cellularity, low proliferation and focal diffuse brain infiltration. Patients typically had seizures since childhood and all were operated on as adults. To define the position of these lesions among brain tumours, we histologically, molecularly and clinically analysed 26 histologically prototypical isomorphic diffuse gliomas. Immunohistochemically, they were GFAP-positive, MAP2-, OLIG2- and CD34-negative, nuclear ATRX-expression was retained and proliferation was low. All 24 cases sequenced were IDH-wildtype. In cluster analyses of DNA methylation data, isomorphic diffuse gliomas formed a group clearly distinct from other glial/glio-neuronal brain tumours and normal hemispheric tissue, most closely related to paediatric MYB/MYBL1-altered diffuse astrocytomas and angiocentric gliomas. Half of the isomorphic diffuse gliomas had copy number alterations of MYBL1 or MYB (13/25, 52%). Gene fusions of MYBL1 or MYB with various gene partners were identified in 11/22 (50%) and were associated with an increased RNA-expression of the respective MYB-family gene. Integrating copy number alterations and available RNA sequencing data, 20/26 (77%) of isomorphic diffuse gliomas demonstrated MYBL1 (54%) or MYB (23%) alterations. Clinically, 89% of patients were seizure-free after surgery and all had a good outcome. In summary, we here define a distinct benign tumour class belonging to the family of MYB/MYBL1-altered gliomas. Isomorphic diffuse glioma occurs both in children and adults, has a concise morphology, frequent MYBL1 and MYB alterations and a specific DNA methylation profile. As an exclusively histological diagnosis may be very challenging and as paediatric MYB/MYBL1-altered diffuse astrocytomas may have the same gene fusions, we consider DNA methylation profiling very helpful for their identification.
2004 年,在组织学上确定了“弥漫性星形细胞瘤同形亚型”,这是一种幕上高度分化的胶质瘤,具有低细胞性、低增殖和局灶性弥漫性脑浸润。患者通常在儿童时期就有癫痫发作,且均在成年后接受手术治疗。为了确定这些病变在脑肿瘤中的位置,我们对 26 例组织学典型的同形弥漫性神经胶质瘤进行了组织学、分子学和临床分析。免疫组化显示它们 GFAP 阳性,MAP2、OLIG2 和 CD34 阴性,核 ATRX 表达保留,增殖率低。所有测序的 24 例病例均为 IDH 野生型。在 DNA 甲基化数据的聚类分析中,同形弥漫性神经胶质瘤形成了一个与其他神经胶质/神经胶质神经元脑肿瘤和正常半球组织明显不同的群组,与小儿 MYB/MYBL1 改变的弥漫性星形细胞瘤和血管中心性胶质瘤最为密切相关。一半的同形弥漫性神经胶质瘤存在 MYBL1 或 MYB 的拷贝数改变(13/25,52%)。在 22 例中有 11 例(50%)鉴定到 MYBL1 或 MYB 与各种基因伙伴的基因融合,与各自的 MYB 家族基因的 RNA 表达增加相关。整合拷贝数改变和可用的 RNA 测序数据,26 例中有 20 例(77%)的同形弥漫性神经胶质瘤显示 MYBL1(54%)或 MYB(23%)改变。临床方面,89%的患者术后无癫痫发作,且均有良好的预后。总之,我们在这里定义了一个属于 MYB/MYBL1 改变的神经胶质瘤家族的独特良性肿瘤类别。同形弥漫性神经胶质瘤发生在儿童和成人中,形态学简洁,频繁发生 MYBL1 和 MYB 改变,具有特定的 DNA 甲基化模式。由于仅进行组织学诊断可能极具挑战性,并且小儿 MYB/MYBL1 改变的弥漫性星形细胞瘤可能具有相同的基因融合,因此我们认为 DNA 甲基化分析对其识别非常有帮助。